Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
Phase 2
Completed
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01115491
A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma
Phase 1
Completed
- Conditions
- Malignant Melanoma
- Interventions
- Drug: RO5185426
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT01107418
An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia
Completed
- Conditions
- Anemia
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6000
- Registration Number
- NCT01105494
A Study on the Effect of Renal Function on the Pharmacakokinetics of RO5024048 (Parent of Prodrug RO5024048) Following Multiple Oral Dose Administration of RO5024048
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: RO5024048
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT01099904
A Study of Balapiravir in Patients With Dengue Virus Infection
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 64
- Registration Number
- NCT01096576
A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)
Phase 3
Completed
- Conditions
- Hepatitis B, Chronic
- Interventions
- Drug: Pegylated interferon (PEG-IFN) alfa-2a, 180 mcgDrug: Pegylated interferon (PEG-IFN) alfa-2a, 135 mcgDrug: Lamivudine (LAM)
- First Posted Date
- 2010-03-30
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 131
- Registration Number
- NCT01095835
A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
Phase 4
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-03-26
- Last Posted Date
- 2018-03-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 49
- Registration Number
- NCT01094184
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 95
- Registration Number
- NCT01089023
Observational Study of Bevacizumab [Avastin] in Patients With Metastatic Colorectal Cancer (AVASTART)
- First Posted Date
- 2010-03-18
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 201
- Registration Number
- NCT01089413
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
Phase 3
Completed
- Conditions
- Hepatitis D, Chronic
- Interventions
- First Posted Date
- 2010-03-17
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT01088659
- Locations
- 🇹🇷
Dokuz Eylul University Medical Faculty; Infection, Izmir, Turkey
🇹🇷Istanbul Uni Cerrahpasa Medical Faculty; Gastroenterolgy, Istanbul, Turkey
🇹🇷Ankara University Medical Facility; Hepatology Department, Ankara, Turkey
© Copyright 2025. All Rights Reserved by MedPath